FDA Clears Daily Pill Pimjetmi for Rare Joint Tumor TGCT
The once-daily drug becomes the third of its class cleared for a tumor that can stiffen and damage joints, after a trial showed most patients' tumors shrank.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
U.S. regulators have approved pimicotinib, sold as Pimjetmi by EMD Serono, to treat symptomatic tenosynovial giant cell tumor, or…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
4 confirmed facts, 2 open questions and 2 sources behind this story.